AN2 Therapeutics, Inc. (ANTX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, AN2 Therapeutics reported revenue of $0. Net income was -$35.2M, or -$1.16 per diluted share. Operating activities generated -$29.8M of cash. At fiscal year end, AN2 Therapeutics held $62.0M in total assets against $8.9M in total liabilities, including $19.9M of cash and equivalents.
Open the full interactive AN2 Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
AN2 Therapeutics Key Stats
| Share Price | $3.60 |
|---|---|
| Market Cap | $161.1M |
| 52-Week Range | $1.03 – $6.28 |
| Shares Outstanding | 44.8 million (basic, 2026 Q2) |
AN2 Therapeutics Income Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating Income | -$42.3M | -$69.6M | -$56.8M | -$38.1M |
| Pre-Tax Income | -$41.0M | -$64.7M | -$51.3M | -$35.2M |
| Income Tax | $0 | $0 | $0 | $0 |
| Net Income | -$41.0M | -$64.7M | -$51.3M | -$35.2M |
| Diluted EPS | -$2.79 | -$2.74 | -$1.72 | -$1.16 |
AN2 Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$9.4M | -$8.7M | -$10.0M | -$8.2M |
| Diluted EPS | -$0.31 | -$0.29 | -$0.29 | -$0.18 |
AN2 Therapeutics Balance Sheet
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash & Equivalents | $27.2M | $15.6M | $21.4M | $19.9M |
| Current Assets | $98.6M | $110.5M | $86.3M | $59.9M |
| Total Assets | $102.6M | $138.7M | $92.1M | $62.0M |
| Current Liabilities | $7.2M | $14.0M | — | $8.7M |
| Total Liabilities | $7.2M | $14.0M | $10.2M | $8.9M |
| Shareholders' Equity | $95.4M | $124.7M | $81.8M | $53.1M |
AN2 Therapeutics Cash Flow Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash From Operations | -$33.5M | -$53.3M | -$49.3M | -$29.8M |
| Cash From Investing | -$21.8M | -$43.3M | $54.6M | $28.3M |
| Cash From Financing | $70.4M | $85.0M | $372,000 | $113,000 |
Figures from AN2 Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full AN2 Therapeutics financials page for every line item.
AN2 Therapeutics Company Profile
| Ticker | ANTX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Menlo Park, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company, emerging growth company |
| SEC CIK | 0001880438 |
Frequently Asked Questions
What was AN2 Therapeutics' revenue in fiscal 2025?
AN2 Therapeutics (ANTX) reported revenue of $0 for fiscal 2025.
What is AN2 Therapeutics' annual revenue history?
AN2 Therapeutics' annual revenue by fiscal year: 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was AN2 Therapeutics' net income in fiscal 2025?
AN2 Therapeutics reported net income of -$35.2M for fiscal 2025.
What was AN2 Therapeutics' earnings per share (EPS) in fiscal 2025?
AN2 Therapeutics' diluted EPS was -$1.16 for fiscal 2025 (adjusted for any later stock splits).
What was AN2 Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), AN2 Therapeutics reported revenue of $0.
How many shares of AN2 Therapeutics are outstanding?
AN2 Therapeutics reported a weighted average of 44.8 million basic shares outstanding in 2026 Q2.
What is AN2 Therapeutics' market cap?
Based on its latest closing price, AN2 Therapeutics (ANTX) has a market capitalization of about $161.1M.
When does AN2 Therapeutics' fiscal year end?
AN2 Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is AN2 Therapeutics headquartered?
AN2 Therapeutics lists its business address in Menlo Park, California in its SEC filings.